Literature DB >> 11313297

D(1) dopamine receptors potentiate nmda-mediated excitability increase in layer V prefrontal cortical pyramidal neurons.

J Wang1, P O'Donnell.   

Abstract

The interactions between N-methyl-D-aspartate (NMDA) and D(1) dopamine receptors in the rat prefrontal cortex were examined using whole-cell recordings from pyramidal neurons. The effects of NMDA, the D(1) agonist SKF38393, or both compounds combined were tested on measures of cell excitability. Both NMDA (10-100 microM) and SKF38393 (5-10 microM) independently increased the number of spikes and decreased the latency of the first spike evoked by intracellular depolarizing current pulses. Combining low doses of NMDA (5 microM) and SKF38393 (2 microM) resulted in a marked increase of cell excitability. This synergism was blocked by SCH23390, protein kinase A (PKA) inhibitors, and the Ca(2+) chelator BAPTA, and reduced by nifedipine. These results indicate the presence of a dopamine- glutamate interaction in the prefrontal cortex at the postsynaptic level, by which D(1) dopamine receptors may maintain NMDA- mediated responses in prefrontal cortical pyramidal neurons through both a PKA-dependent pathway and Ca(2+)-dependent mechanisms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313297     DOI: 10.1093/cercor/11.5.452

Source DB:  PubMed          Journal:  Cereb Cortex        ISSN: 1047-3211            Impact factor:   5.357


  74 in total

Review 1.  The neuroscience of natural rewards: relevance to addictive drugs.

Authors:  Ann E Kelley; Kent C Berridge
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

2.  Action potential initiation and propagation in layer 5 pyramidal neurons of the rat prefrontal cortex: absence of dopamine modulation.

Authors:  Allan T Gulledge; Greg J Stuart
Journal:  J Neurosci       Date:  2003-12-10       Impact factor: 6.167

3.  Spontaneous voltage oscillations in striatal projection neurons in a rat corticostriatal slice.

Authors:  R Vergara; C Rick; S Hernández-López; J A Laville; J N Guzman; E Galarraga; D J Surmeier; J Bargas
Journal:  J Physiol       Date:  2003-09-08       Impact factor: 5.182

Review 4.  Toward a neurobiology of delusions.

Authors:  P R Corlett; J R Taylor; X-J Wang; P C Fletcher; J H Krystal
Journal:  Prog Neurobiol       Date:  2010-06-15       Impact factor: 11.685

5.  Differential effects of clozapine and haloperidol on interval timing in the supraseconds range.

Authors:  Christopher J MacDonald; Warren H Meck
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

6.  Acute stress and nicotine cues interact to unveil locomotor arousal and activity-dependent gene expression in the prefrontal cortex.

Authors:  Craig A Schiltz; Ann E Kelley; Charles F Landry
Journal:  Biol Psychiatry       Date:  2006-04-21       Impact factor: 13.382

7.  Dopaminergic modulation of striatal plateau depolarizations in corticostriatal organotypic cocultures.

Authors:  Kuei Y Tseng; Abigail Snyder-Keller; Patricio O'Donnell
Journal:  Psychopharmacology (Berl)       Date:  2006-06-07       Impact factor: 4.530

8.  The dopaminergic stabilizers pridopidine and ordopidine enhance cortico-striatal Arc gene expression.

Authors:  Susanna Waters; Henrik Ponten; Malin Edling; Boel Svanberg; Daniel Klamer; Nicholas Waters
Journal:  J Neural Transm (Vienna)       Date:  2014-05-11       Impact factor: 3.575

9.  Calcyon forms a novel ternary complex with dopamine D1 receptor through PSD-95 protein and plays a role in dopamine receptor internalization.

Authors:  Chang Man Ha; Daehun Park; Jeong-Kyu Han; June-ill Jang; Jae-Yong Park; Eun Mi Hwang; Heon Seok; Sunghoe Chang
Journal:  J Biol Chem       Date:  2012-07-26       Impact factor: 5.157

Review 10.  Plasticity at hippocampal to prefrontal cortex synapses is impaired by loss of dopamine and stress: importance for psychiatric diseases.

Authors:  Thérèse M Jay; Cyril Rocher; Maïte Hotte; Laurent Naudon; Hirac Gurden; Michael Spedding
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.